Literature DB >> 11917248

Pleural and peritoneal lymphoma among people with AIDS in the United States.

Sam M Mbulaiteye1, Robert J Biggar, James J Goedert, Eric A Engels.   

Abstract

OBJECTIVE: To describe the occurrence and characteristics of pleural and peritoneal lymphoma in a large cohort of persons with AIDS in 11 regions in the United States.
METHODS: We used AIDS and cancer registries to identify cases of non-Hodgkin lymphoma (NHL) among 304,439 adults with AIDS. NHLs were categorized by site codes into pleural/peritoneal lymphoma and other NHLs. Data on age, sex, HIV exposure category, histology, history of Kaposi sarcoma (KS), CD4 counts, and survival were analyzed.
RESULTS: Fourteen lymphomas were identified (four within the pleura, 10 in the peritoneum) representing 0.13% (95% confidence interval [CI], 0.05-0.20) of 10,510 cases of NHL. Those with pleural/peritoneal lymphoma were similar to those with other NHLs in age (median, 43 years), race (79% white, 7% black, 14% Hispanic), and HIV transmission category (86% homosexual men), but they tended to have a higher prevalence of prior KS (29% vs. 12%; p =.06). More cases of pleural/peritoneal lymphoma had immunoblastic histology than did other NHLs (43% vs. 22%; p =.06). CD4 counts for pleural/peritoneal lymphomas were also higher than for other NHLs (median 203 vs. 65 cells/mm3; p =.05), but post-NHL survival was similar (median 7.1 vs. 5.1 months, respectively; p =.32).
CONCLUSIONS: Pleural and peritoneal lymphomas are a rare subtype of AIDS-associated NHL, occurring with less severe immune deficiency than for other NHLs. The increased frequency among persons with prior KS suggests a common etiology, presumably infection with KS-associated herpesvirus, as found in primary effusion lymphoma.

Entities:  

Mesh:

Year:  2002        PMID: 11917248     DOI: 10.1097/00126334-200204010-00014

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  8 in total

Review 1.  The viral etiology of AIDS-associated malignancies.

Authors:  Peter C Angeletti; Luwen Zhang; Charles Wood
Journal:  Adv Pharmacol       Date:  2008

2.  Infection of primary human tonsillar lymphoid cells by KSHV reveals frequent but abortive infection of T cells.

Authors:  Jinjong Myoung; Don Ganem
Journal:  Virology       Date:  2011-02-25       Impact factor: 3.616

Review 3.  Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis.

Authors:  Lyubomir A Dourmishev; Assen L Dourmishev; Diana Palmeri; Robert A Schwartz; David M Lukac
Journal:  Microbiol Mol Biol Rev       Date:  2003-06       Impact factor: 11.056

4.  Primary effusion lymphoma associated with Human Herpes Virus-8 and Epstein Barr virus in an HIV-infected woman from Kampala, Uganda: a case report.

Authors:  Lynnette K Tumwine; Rejani Lalitha; Claudio Agostinelli; Simon Luzige; Jackson Orem; Pier Paolo Piccaluga; Lawrence O Osuwat; Stefano A Pileri
Journal:  J Med Case Rep       Date:  2011-02-14

Review 5.  Human herpesvirus 8--a novel human pathogen.

Authors:  Daniel C Edelman
Journal:  Virol J       Date:  2005-09-02       Impact factor: 4.099

6.  A Unique Case of Malignant Pleuropericardial Effusion: HHV-8-Unrelated PEL-Like Lymphoma-A Case Report and Review of the Literature.

Authors:  Farhan Mohammad; Muhammad Neaman Siddique; Faraz Siddiqui; M Popalzai; Masoud Asgari; Marcel Odaimi
Journal:  Case Rep Oncol Med       Date:  2014-03-04

7.  A case-control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda.

Authors:  Tharcisse Mpunga; Ariana Znaor; F Regis Uwizeye; Aline Uwase; Cyprien Munyanshongore; Silvia Franceschi; Gary M Clifford
Journal:  Int J Cancer       Date:  2018-04-26       Impact factor: 7.396

8.  Extracavitary manifestation of primary effusion lymphoma as a right atrial mass.

Authors:  Creticus P Marak; Ana M Ponea; Chang Shim; Shagufta Shaheen; Achuta K Guddati
Journal:  Case Rep Oncol       Date:  2013-02-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.